Self-Administered Gerocognitive Examination (SAGE) Score Changes over Time in Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), Dementia Converters, and Alzheimer’s Disease (AD) Patients (P4.088)

Abstract

OBJECTIVE: To determine change in SAGE scores over time in individuals with various clinical diagnoses. BACKGROUND: SAGE is a valid self-administered cognitive assessment tool for detecting cognitive impairment including MCI and mild dementia. DESIGN/METHODS: Retrospective chart review from October 2005 through August 2014 was performed on consecutive subjects seen in the Memory Disorders Clinic at Ohio State University who had at least 2 SAGE tests done at least 6 months apart. Additional neuropsychological testing (CERAD battery) performed in all subjects was the sole basis of determination of normal or impaired cognition. Individuals with normal cognition despite cognitive complaints and basically no deficits in Activities of Daily Living (ADL) were classified as SCI. Individuals with mildly impaired cognition and no or minimal decline in ADL were classified as MCI. MCI individuals who developed, over time, significantly impaired cognition and decline in ADL sufficient to meet criteria for dementia were classified as Converters. AD patients met the diagnostic criteria of DSM-IV and NINCDS-ADRDA. One way and repeated measures ANOVAs were preformed. RESULTS: 440 individuals (46 SCI, 98 MCI non-converters, 70 Converters, 226 AD) met the inclusion criteria. Baseline mean SAGE scores (out of 22) for SCI (19.7±2.0) was significantly different than MCI non-converters (17.1±3.3), Converters (16.5±3.1), and AD (10.7±4.7) groups. However, baseline SAGE scores were not significantly different for the MCI non-converter and Converter groups. SAGE scores declined significantly over time (p<0.0001) for Converters (-1.97 points/year) and AD (-1.79 points/year) but not for SCI (0.10 points/year) or MCI non-converters (0.03 point/year) (p>0.05). CONCLUSIONS: SAGE scores were stable over time in SCI and MCI who did not convert to dementia. Those with declining SAGE scores were at high risk for dementia diagnosis. The ease of repetitively giving the self-administered SAGE and identification of score stability or decline may provide clinicians significant diagnostic assistance.

Disclosure: Dr. Scharre has received personal compensation for activities with Eli Lilly & Company as a consultant. Dr. Chang has received research support from the Harry T. Mangurian Jr. Foundation. Dr. Nagaraja has received research support from the Mangurian Foundation. Dr. Kataki has received research support from Pfizer Inc., Lundbeck Research USA, Inc., Merck, Avinar Pharmaceuticals, Eli Lilly & Co., EnVivo Pharmaceuticals, AstraZeneca, Phylogeny, Inc. and the Harry T. Mangurian Jr. Foundation. Dr. Wheeler has nothing to disclose. Dr. Adeli has received research support from Pfizer, Lundbeck, Avanir, Merck, Eli Lillly, Envivo, and AstraZeneca.